Personal wellness company WeightWatchers (NASDAQ: WW) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 6.4% year on year to $189.2 million. On the other hand, the company’s full-year revenue guidance of $692.5 million at the midpoint came in 1.1% below analysts’ estimates. Its GAAP profit of $14.68 per share increased from $0.29 in the same quarter last year.

Is now the time to buy WW? Find out in our full research report (it’s free).

StockStory’s Take

WeightWatchers’ second quarter results were met with a negative market reaction, as the company faced a year-over-year revenue decline and ongoing member attrition. Management attributed these trends to challenges in acquiring new behavioral members and a significant shift in the clinical business after regulatory changes around compounded weight loss medications. CEO Tara Comonte described the quarter as a “pivotal moment,” emphasizing the impact of transitioning members away from compounded semaglutide and lingering effects from bankruptcy proceedings. Chief Financial Officer Felicia DellaFortuna noted that, despite growth in clinical subscriber revenue, overall member acquisition remained pressured throughout the quarter.

Looking forward, management’s guidance is shaped by efforts to stabilize the core business and reposition WeightWatchers for long-term growth. The company is investing in technology upgrades, expanding clinical offerings, and targeting adjacent wellness segments such as women’s health. Comonte said, “We are focused on disciplined execution and meaningful innovation,” while highlighting ongoing headwinds from competitive pressures and regulatory uncertainty in the GLP-1 medication landscape. The leadership team cautioned that the effects of recent subscriber losses will continue to influence results into next year.

Key Insights from Management’s Remarks

Management pointed to the interplay between regulatory changes, strategic reorganization, and innovation in care delivery as the primary influences on quarterly performance and guidance.

• GLP-1 medication transition: The discontinuation of compounded semaglutide, following new FDA guidance, required the company to move clinical members to FDA-approved alternatives. This disrupted subscriber growth but was necessary for regulatory compliance and long-term positioning.
• Debt reduction and reorganization: WeightWatchers completed a strategic financial restructuring, reducing debt by over 70% and freeing up cash flow. Management sees this as essential for renewed investment and operational flexibility.
• Member experience overhaul: The company is focusing on a seamless, personalized member experience across digital and in-person channels. The appointment of Julie Rice as Chief Experience Officer, and integration of her prior company’s wellness curriculum, are central to this effort.
• Expansion of clinical and adjacent offerings: Management highlighted growth in the clinical business, especially through insurance-enabled access to GLP-1 medications and the forthcoming launch of new programs targeting menopause and women’s health.
• Operational discipline and cost savings: Adjusted EBITDA margin gains stemmed from strict cost management, reduced marketing expenses during reorganization, and ongoing integration of technology and automation to drive efficiency.

Drivers of Future Performance

WeightWatchers’ near-term outlook is shaped by ongoing clinical market changes, technology investments, and a renewed focus on expanding into adjacent health categories.

• Competitive GLP-1 landscape: The company expects continuing headwinds as some telehealth competitors persist in offering compounded GLP-1 medications, impacting both member retention and acquisition until regulatory enforcement is more consistent.
• Broader wellness and women’s health: Management is prioritizing new product launches, particularly in women’s health and menopause support, to diversify revenue streams and reduce reliance on the core weight loss segment.
• Technology and operational upgrades: Investments in data infrastructure, AI-powered personalization, and automation are expected to drive engagement and efficiency, though these efforts will take time to fully materialize in financial results.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) member retention and subscriber trends as the transition from compounded to FDA-approved GLP-1 medications continues, (2) execution of technology and personalization upgrades to the member experience, and (3) early traction of new women’s health and menopause programs. The pace of B2B channel recovery and regulatory developments in obesity care will also be key signposts.

WeightWatchers currently trades at $36.77, down from $38.11 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.